Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

iBio

DB:0JVN
Snowflake Description

Weak fundamentals or lack of information.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
0JVN
DB
$71M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

iBio, Inc., a biotechnology company, provides product development and manufacturing services to clients, collaborators, and third-party customers in the United States and internationally. The last earnings update was 52 days ago. More info.


Add to Portfolio Compare Print
  • iBio has significant price volatility in the past 3 months.
0JVN Share Price and Events
7 Day Returns
-12.3%
DB:0JVN
-0.7%
DE Biotechs
-0.6%
DE Market
1 Year Returns
28%
DB:0JVN
-13.2%
DE Biotechs
-20.9%
DE Market
0JVN Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
iBio (0JVN) -12.3% -47.4% 310.6% 28% -75.4% -90%
DE Biotechs -0.7% -8.2% -21% -13.2% 13.2% -11.8%
DE Market -0.6% -18.6% -26.2% -20.9% -25.8% -31.8%
1 Year Return vs Industry and Market
  • 0JVN outperformed the Biotechs industry which returned -13.2% over the past year.
  • 0JVN outperformed the Market in Germany which returned -20.9% over the past year.
Price Volatility
0JVN
Industry
5yr Volatility vs Market
Related Companies

Value

 Is iBio undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether iBio is trading at an attractive price based on the cash flow it is expected to produce in the future. But as iBio has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for iBio. This is due to cash flow or dividend data being unavailable. The share price is €0.895.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for iBio's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are iBio's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:0JVN PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-1.58
AMEX:IBIO Share Price ** AMEX (2020-04-03) in USD $0.94
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 40.67x
Germany Market PE Ratio Median Figure of 401 Publicly-Listed Companies 16.57x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of iBio.

DB:0JVN PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= AMEX:IBIO Share Price ÷ EPS (both in USD)

= 0.94 ÷ -1.58

-0.59x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • iBio is loss making, we can't compare its value to the Europe Biotechs industry average.
  • iBio is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does iBio's expected growth come at a high price?
Raw Data
DB:0JVN PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.59x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.62x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.17x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for iBio, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on iBio's assets?
Raw Data
DB:0JVN PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $-0.01
AMEX:IBIO Share Price * AMEX (2020-04-03) in USD $0.94
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.33x
Germany Market PB Ratio Median Figure of 572 Publicly-Listed Companies 1.44x
DB:0JVN PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= AMEX:IBIO Share Price ÷ Book Value per Share (both in USD)

= 0.94 ÷ -0.01

-99.85x

* Primary Listing of iBio.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • iBio has negative assets, we can't compare the value of its assets to the DE Biotechs industry average.

Next steps:

  1. Take a look at our analysis of 0JVN’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through iBio's regulatory filings and announcements.
  3. Show me more potentially undervalued companies in the Biotechs industry
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess iBio's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. iBio has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is iBio expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as iBio has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
55.2%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is iBio expected to grow at an attractive rate?
  • Unable to compare iBio's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare iBio's earnings growth to the Germany market average as no estimate data is available.
  • Unable to compare iBio's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:0JVN Future Growth Rates Data Sources
Data Point Source Value (per year)
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 55.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 24%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:0JVN Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:0JVN Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 2 -14 -39
2019-09-30 2 -15 -18
2019-06-30 2 -14 -18
2019-03-31 1 -13 -18
2018-12-31 1 -12 -18
2018-09-30 0 -11 -17
2018-06-30 0 -13 -16
2018-03-31 1 -14 -16
2017-12-31 0 -14 -16
2017-09-30 0 -14 -15
2017-06-30 0 -13 -15
2017-03-31 1 -12 -13

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if iBio is high growth as no earnings estimate data is available.
  • Unable to determine if iBio is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:0JVN Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from iBio Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:0JVN Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -1.58
2019-09-30 -0.90
2019-06-30 -0.94
2019-03-31 -1.05
2018-12-31 -1.17
2018-09-30 -1.32
2018-06-30 -1.54
2018-03-31 -1.64
2017-12-31 -1.75
2017-09-30 -1.72
2017-06-30 -1.64
2017-03-31 -1.45

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if iBio will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Take a look at our analysis of 0JVN’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. iBio's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. iBio's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess iBio's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
iBio has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has iBio performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare iBio's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • iBio does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare iBio's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare iBio's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
iBio's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from iBio Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:0JVN Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 1.74 -38.77 11.46 4.94
2019-09-30 2.08 -17.92 12.27 5.33
2019-06-30 2.02 -17.85 12.15 5.47
2019-03-31 1.31 -17.77 12.10 4.89
2018-12-31 0.87 -17.51 11.86 4.41
2018-09-30 0.37 -16.94 11.06 4.13
2018-06-30 0.44 -16.37 10.69 3.99
2018-03-31 0.50 -16.28 10.58 4.06
2017-12-31 0.46 -16.19 10.82 4.23
2017-09-30 0.38 -15.45 10.58 4.28
2017-06-30 0.39 -14.62 10.55 4.12
2017-03-31 0.52 -12.91 9.83 3.86
2016-12-31 0.86 -12.00 9.40 3.77
2016-09-30 0.92 -11.02 8.73 3.43
2016-06-30 0.95 -9.76 7.69 3.16
2016-03-31 0.99 -8.97 6.96 3.07
2015-12-31 0.96 -7.61 5.78 2.83
2015-09-30 1.19 -7.02 5.39 2.86
2015-06-30 1.85 -6.63 5.02 3.50
2015-03-31 1.74 -5.88 4.51 3.15
2014-12-31 1.39 -5.48 4.24 2.68
2014-09-30 1.02 -5.46 3.99 2.53
2014-06-30 0.21 -3.67 3.89 1.90
2014-03-31 0.62 -3.84 3.90 2.45
2013-12-31 0.62 -4.32 4.18 2.74
2013-09-30 0.62 -3.77 4.17 2.81
2013-06-30 1.01 -6.20 4.24 3.43

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if iBio has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if iBio has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if iBio improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess iBio's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
iBio has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is iBio's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up iBio's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • iBio's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • iBio's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of iBio's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • iBio has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from iBio Company Filings, last reported 3 months ago.

DB:0JVN Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 -0.52 0.00 3.64
2019-09-30 -1.94 0.00 2.10
2019-06-30 2.46 0.00 4.42
2019-03-31 6.90 0.00 9.04
2018-12-31 11.08 0.00 13.36
2018-09-30 13.03 0.00 16.01
2018-06-30 16.16 0.00 15.93
2018-03-31 4.15 0.00 3.40
2017-12-31 7.81 0.00 7.31
2017-09-30 6.29 0.00 5.92
2017-06-30 8.92 0.00 8.09
2017-03-31 12.95 0.00 12.42
2016-12-31 17.15 0.00 16.33
2016-09-30 20.70 0.00 20.10
2016-06-30 24.04 0.00 23.01
2016-03-31 22.92 0.00 21.89
2015-12-31 7.88 0.00 6.73
2015-09-30 9.81 0.00 8.38
2015-06-30 11.23 0.00 9.49
2015-03-31 10.19 0.33 8.08
2014-12-31 9.57 0.34 7.36
2014-09-30 5.44 0.56 3.49
2014-06-30 6.10 0.00 3.59
2014-03-31 7.00 0.00 4.33
2013-12-31 7.95 0.00 5.68
2013-09-30 5.68 0.10 3.44
2013-06-30 5.07 1.70 4.41
  • iBio has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if iBio's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • iBio has less than a year of cash runway based on current free cash flow.
  • iBio has less than a year of cash runway if free cash flow continues to grow at historical rates of 23.3% each year.
X
Financial health checks
We assess iBio's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. iBio has a total score of 0/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is iBio's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from iBio dividends.
If you bought €2,000 of iBio shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate iBio's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate iBio's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:0JVN Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 316 Stocks 3.9%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.7%
Germany Top 25% Dividend Yield 75th Percentile 4.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as iBio has not reported any payouts.
  • Unable to verify if iBio's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of iBio's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as iBio has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess iBio's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can iBio afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. iBio has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of iBio's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Tom Isett
COMPENSATION $66,872
AGE 54
TENURE AS CEO 0.1 years
CEO Bio

Mr. Thomas F. Isett lll, also known as Tom, has been a Director at iBio, Inc. since April 1, 2019 and also serves as Co-Chairman and Chief Executive Officer at iBio, Inc. since March, 2020. Mr. Isett is an accomplished executive with decades of successful management and corporate development experience in the life sciences, with notable focus upon biologics contract development and manufacturing organizations (CDMOs). In 2015, he founded i.e. Advising, LLC, a management and strategy consulting firm, as well as Commence Bio, Inc., a private, early-stage developer of cellular immunotherapies. As Managing Director of i.e. Advising - and in his earlier corporate development roles – Mr. Isett has advised Fortune 500 companies, private equity firms, biotechs, and standards-setting organizations on key strategy, M&A, and intellectual property decisions in life sciences. Over the course of his career, he has been involved in dozens of transactions cumulatively valued at over $20 billion. Prior to his founding of i.e. Advising, Mr. Isett held leadership roles for bioprocess product and service businesses over his 25 combined years with GE, Lonza, and BD. Mr. Isett was the founder of Becton Dickinson’s BD Advanced Bioprocessing business, which he led from inception to over $60 million in revenues by 2009; by 2018, revenues reached $100 million and the business was sold for $477 million. At Lonza, he contributed to the rapid growth of the cell & gene therapy CDMO unit as Head of Cell Processing Technologies. Notably, while with GE Life Sciences, he accelerated growth for the North American BioProcess business via the introduction of an integrated solutions strategy, along with new commercial and operating mechanisms to support execution.

CEO Compensation
  • Insufficient data for Tom to compare compensation growth.
  • Tom's remuneration is lower than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the iBio management team in years:

3.1
Average Tenure
54
Average Age
  • The tenure for the iBio management team is about average.
Management Team

Tom Isett

TITLE
Co-Chairman & CEO
COMPENSATION
$67K
AGE
54
TENURE
0.1 yrs

Robert Erwin

TITLE
President
COMPENSATION
$275K
AGE
66
TENURE
11.7 yrs

James Mullaney

TITLE
Chief Financial Officer
COMPENSATION
$319K
AGE
48
TENURE
3.1 yrs

Renato Lobo

TITLE
Chief Medical Officer

R. Holtz

TITLE
President of iBio CDMO
TENURE
1.3 yrs

Carlos Picosse

TITLE
Chief Executive Officer of IBio Brazil
TENURE
6.4 yrs

Betsy Moyle

TITLE
Secretary
Board of Directors Tenure

Average tenure and age of the iBio board of directors in years:

8.7
Average Tenure
74.5
Average Age
  • The tenure for the iBio board of directors is about average.
Board of Directors

Robert Kay

TITLE
Co-Chairman of the Board
COMPENSATION
$348K
AGE
79
TENURE
0.1 yrs

Tom Isett

TITLE
Co-Chairman & CEO
COMPENSATION
$67K
AGE
54
TENURE
0.1 yrs

James Hill

TITLE
Independent Director
COMPENSATION
$77K
AGE
73
TENURE
11.7 yrs

Glenn Chang

TITLE
Independent Director
COMPENSATION
$52K
AGE
71
TENURE
11.7 yrs

Vidadi Yusibov

TITLE
Member of Scientific Advisory Board
AGE
58
TENURE
15.6 yrs

Philip Russell

TITLE
Independent Director
COMPENSATION
$52K
AGE
87
TENURE
10.1 yrs

John McKey

TITLE
Independent Director
COMPENSATION
$52K
AGE
76
TENURE
11.7 yrs

Seymour Flug

TITLE
Independent Director
COMPENSATION
$52K
AGE
84
TENURE
7.3 yrs

Timothy Blackwell

TITLE
Member of Clinical Advisory Board
TENURE
5.8 yrs

Richard Silver

TITLE
Member of Clinical Advisory Board
TENURE
5.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess iBio's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. iBio has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

iBio, Inc., a biotechnology company, provides product development and manufacturing services to clients, collaborators, and third-party customers in the United States and internationally. The company’s services cover the stages of pre-clinical development, regulatory approval, commercial product launch, and on-going commercial phase requirements. Its lead therapeutic candidate is IBIO-CFB03 for the treatment of systemic scleroderma, idiopathic pulmonary fibrosis, and other fibrotic diseases. The company is also developing vaccine candidates for third parties. It has a license agreement with the University of Natural Resources and Life Sciences, Vienna; a strategic relationship with Beijing CC-Pharming Ltd.; and collaboration agreements with AzarGen Biotechnologies (Pty) Ltd, The Texas A&M University System, and Fraunhofer Center for Molecular Biotechnology. In addition, the company offers a range of product and process development, analytical, and manufacturing services. iBio, Inc. is headquartered in New York, New York.

Details
Name: iBio, Inc.
0JVN
Exchange: DB
Founded:
$66,034,905
76,195,455
Website: http://www.ibioinc.com
Address: iBio, Inc.
600 Madison Avenue,
Suite 1601,
New York,
New York, 10022,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
AMEX IBIO Common Stock NYSE MKT LLC US USD 18. Aug 2008
DB 0JVN Common Stock Deutsche Boerse AG DE EUR 18. Aug 2008
Number of employees
Current staff
Staff numbers
55
iBio employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/06 00:12
End of day share price update: 2020/04/03 00:00
Last earnings filing: 2020/02/14
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/06/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.